In brief
The FDA's approval of a new generic version of mifepristone has triggered fierce criticism from anti-abortion groups aligned with the Trump administration. Drug manufacturer Evita Solutions announced the approval on its website, stating that the low-cost option is designed for terminating pregnancies within the first ten weeks. Following the approval, prominent figures such as Health Secretary Robert F. Kennedy Jr. have pledged to reassess the safety of mifepristone. This decision comes in the backdrop of escalating access debates surrounding abortion medications, juxtaposed with ongoing legal challenges across various states.
WASHINGTON (AP) — The U.S. Food and Drug Administration (FDA) has approved a new generic formulation of the abortion pill, mifepristone, a development that has been met with significant backlash from anti-abortion advocates linked to the Trump administration.
Evita Solutions, the manufacturer, has made the announcement on their official website, detailing that the new low-cost formulation is intended for use in ending pregnancies up to 10 weeks.
In response to the FDA's approval, Students for Life Action, an organization opposing abortion, condemned the action as a stain on the Trump presidency, characterizing it as evidence of corruption within the FDA.
This criticism arises as key health officials from the Trump administration, including Health Secretary Robert F. Kennedy Jr., face intense lobbying from abortion opponents to review the drug’s safety, despite its long-standing approval dating back to 2000 and affirmations of its efficacy by FDA scientists.
In a communication directed to Republican attorneys general, both Kennedy and FDA Commissioner Dr. Marty Makary committed to conducting a comprehensive safety review of mifepristone.
This latest approval is a follow-up to the FDA's previous endorsement of the initial mifepristone generic in 2019, a process widely regarded as standard procedure post-patent expiration.
Since President Joe Biden's administration began in 2021, the FDA has enhanced access to mifepristone by allowing online prescriptions and mail-order delivery, resulting in intensified opposition from anti-abortion factions.
Evita's application for this generic was filed four years ago, and while the approval is generally considered routine, it comes at a time when access to mifepristone is limited due to various state-level abortion bans and ongoing legal disputes.
The combination of mifepristone and misoprostol accounts for approximately two-thirds of all abortions in the United States, with mifepristone functioning to block progesterone—a key hormone for pregnancy—while misoprostol induces uterine contractions.
Current restrictions on mifepristone adoption in parts of the country have been met with opposition from major medical organizations, including the American Medical Association, which does not support such limitations.
